Report: Blood Cancer Drug Discoveries: what the future holds TOC

Blood Cancers
- US incidence of blood cancers, 2007
- Unmet Medical Need
- New Agents In Development
  - New mechanisms of action under investigation for the development of blood cancers:
  - Monoclonal antibodies in development for treatment of blood cancers
- Major Players
  - 2007
    - Market share of players in the worldwide blood cancers market, 2007
  - 2012
    - Market share of players in the worldwide blood cancers market, 2012
- Global Sales
  - Estimated and forecast worldwide sales in the treatment of blood cancers (US$ millions)
  - Regional breakdown of blood cancer market by sales - 2007 and 2012
Chronic Lymphocytic Leukaemia
- Background
- Patient Statistics
  - Patient model
    - Estimated prevalence of CLL in major markets, 2005-2012
- Drug Growth Drivers
- Drug Growth Dampeners
- The Market
  - Global Market
    - Forecast CLL market growth (US$ millions)
  - Major players
    - Current drugs commonly used in the treatment of CLL
    - Major players in CLL by sales - 2007
    - Forecast major players in CLL by sales - 2012
- The Drugs
- Current Drugs
  - Selected response rates from studies of first line treatment of CLL:
- Fludara
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast Fludara sales in CLL by region (US$ millions)
  - Forecast Fludara sales in CLL by use (US$ millions)
  - Competitor ratio analysis
- Rituxan
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast Rituxan sales in CLL by use (US$ millions)
  - Forecast Rituxan sales in CLL by region (US$ millions)
  - Competitor ratio analysis
- Campath
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast Campath sales in CLL by use (US$ millions)
  - Competitor ratio analysis
- Agents in Development
  - Drugs in development for the treatment of CLL
  - Agents in late stage development for CLL:
- Treanda
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast Treanda sales in CLL (US$ millions)
  - Competitor ratio analysis
- Genasense
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Genasense in CLL efficacy summary:
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast Genasense sales in CLL by region (US$ millions):
  - Forecast Genasense sales in CLL by use (US$ millions):
  - Competitor ratio analysis
- Ofatumumab
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast ofatumumab sales in CLL by region (US$millions):
  - Forecast ofatumumab sales in CLL by use (US$millions):
  - Competitor ratio analysis
- Alvocidib
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast alvocidib sales in CLL (US$ millions)
  - Competitor ratio analysis
- Lumliximab
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast lumiliximab sales in CLL (US$ millions)
  - Competitor ratio analysis
- Revlimid
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast Revlimid CLL sales by use (US$ millions):
  - Forecast Revlimid CLL sales by region (US$ millions):
  - Competitor ratio analysis
Chronic Myeloid Leukaemia
- Background
- Patient Statistics
  - Trends in US CML incidence:
  - Estimated incidence in worldwide CML prevalence:
- Drug Growth Drivers
- Drug Growth Dampeners
- The Market
  - Global market
    - Forecast worldwide CML market (US$ millions)
  - Major players - 2007
    - Major players in CML by sales - 2007
  - Major players - 2012
    - Forecast major players in CLL by sales - 2012
- The Drugs
  - CML treatment timeline:
  - Current drugs
    - Current drugs used in the treatment of CML:
- Gleevec/Glivec
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - IRIS study: 18-Month Response Rates Determined by Intent-to-Treat Analysis
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast Gleevec sales in CML (US$ millions) - excludes sales in GIST
  - Competitor ratio analysis
- Sprycel
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
    - Filings and approval
    - Sales forecasts and assumptions
    - Sprycel CML sales (US$ millions):
    - Competitor ratio analysis
- Tasigna
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
    - Competition within the marketplace/gaining share of voice
    - Risks associated with developing a drug within a therapeutic class
    - Filings and approval
    - Sales forecasts and assumptions
    - Tasigna CML sales forecast (US$ millions)
    - Competitor ratio analysis
- Agents in Development
  - Drugs in development for the treatment of CML:
  - Agents in late stage development for CML:
- Bosutinib
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast bosutinib sales in CML (US$ millions)
  - Competitor ratio analysis
- Panobinostat
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Competitor ratio analysis
- MK-0457/ VX 680
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Competitor ratio analysis
Acute Myeloid Leukaemia
- Background
  - French-American-British (FAB) Classification of AML
  - WHO AML classification:
  - Selected risk factors associated with AML:
  - Common chromosomal abnormalities in AML:
- Patient Statistics
  - Forecast incidence of AML by region:
- Drug Growth Drivers
- Drug Growth Dampeners
- The Market
  - Global market
    - Forecast worldwide adult AML market
  - Major players - 2007
  - Major players - 2012
    - Forecast major players in AML by sales - 2012
- The Drugs
  - Treatment naïve patients
  - Relapsed & refractory AML
  - Current drugs used in the treatment of AML:
  - Therapeutic strategies in AML and relapsed/refractory AML:
- Mylotarg
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Summary of response rates in Mylotarg studies:
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Competitor ratio analysis
- Agents in Development
  - Agents in late stage development for AML:
- Clolar/Evoltra
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast sales of Clolar/Evoltra in adult AML (US$ millions):
  - Competitor ratio analysis
- Cloretazine
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast sales of Cloretazine in AML (US$ millions)
  - Competitor ratio analysis
- Zarnestra
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Competitor ratio analysis
- Dacogen
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast Dacogen sales in adult AML (US$ millions)
  - Competitor ratio analysis
- lestaurtinib
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast lestaurtinib sales in AML (US$ millions)
  - Competitor ratio analysis
- midostaurin
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast midostaurin sales in AML (US$ millions)
  - Competitor ratio analysis
- tandutinib
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Competitor ratio analysis
- zosuquidar
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Competitor ratio analysis
- Xanafide
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast Xanafide sales in AML (US$ millions)
  - Competitor ratio analysis
- Ceplene
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast Ceplene sales in AML (US$ millions)
  - Competitor ratio analysis
Multiple Myeloma
- Background
- Patient Statistics
  - Patient model
    - Estimated prevalence of multiple myeloma in selected markets
- Drug Growth Drivers
- Drug Growth Dampeners
- The Market
  - Global market
    - Forecast worldwide multiple myeloma market (US$ millions):
  - Major players
    - Major players in multiple myeloma by sales - 2007
    - Major players in multiple myeloma by sales - 2012
    - Current drugs used in the treatment of multiple myeloma:
- The Drugs
- Thalomid
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast Thalomid sales in multiple myeloma (US$ millions)
  - Competitor ratio analysis
- Revlimid
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Data summary of MM-009 and MM - 010 studies:
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Front line myeloma comparison:
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Competitor ratio analysis
- Velcade
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast Velcade sales in multiple myeloma (US$ millions)
  - Competitor ratio analysis
- Agents in Development
  - Drugs in development for the treatment of multiple myeloma:
  - Agents in late stage development for multiple myeloma:
- Tanespimycin
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
    - Competition within the marketplace/gaining share of voice
    - Risks associated with developing a drug within a therapeutic class
    - Filings and approval
    - Sales forecasts and assumptions
    - Forecast tanespimycin sales in relapsed/refractory multiple myeloma (US$ millions)
    - Competitor ratio analysis
- mapatumumab
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Competitor ratio analysis
- Belinostat
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Competitor ratio analysis
- Perifosine
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Competitor ratio analysis
- Carfilzomib
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Competitor ratio analysis
Non Hodgkin' s Lymphoma
- Background
  - Frequency of NHL subtypes in adults:
  - 1) B-cell CLL /small lymphocytic lymphoma
  - 2) Marginal zone lymphoma
  - 3) Lymphoplasmocytic lymphoma (Waldenstrom macroglobulinemia):
  - 4) Follicular lymphoma:
  - 1) Cutaneous T-cell lymphoma:
  - 1) Diffuse large B-cell lymphoma (DL BCL):
  - 2) Mantle cell lymphoma:
  - 3) Burkitt lymphoma/Burkitt-like lymphoma:
  - 4) Precursor B-cell leukaemia/lymphoma
  - 1) Anaplastic large T/null-cell lymphoma:
  - 2) Precursor T-lymphoblastic lymphoma/leukaemia:
  - 3) Peripheral T-cell lymphomas:
- Staging Systems
- Patient Statistics
  - Patient model
    - Forecast NHL incidence and prevalence (000s)
- Drug Growth Drivers
- Drug Growth Dampeners
- The Market
  - Global market
    - Forecast NHL market (excluding CTCL) - US$ millions
    - Forecast CTCL market - US$ millions
  - Major players
    - Current drugs commonly used in the treatment of NHL
    - Major players in NHL by sales - 2007
    - Major players in NHL by sales - 2012
- The Drugs
  - Low Grade or Indolent NHL
  - Treatment options in indolent/low-grade NHL:
  - Intermediate- and high-grade lymphomas:
  - T-cell lymphomas:
  - Summary of common therapies in NHL
Marketed Agents for use in NHL
- Rituxan
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Rituxan penetration rates, Q3-Q4 2005
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast Rituxan sales in NHL indications by region (US$ millions)
  - Forecast Rituxan sales in NHL indications by use (US$ millions)
  - Competitor ratio analysis
- Fludara
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast Fludara sales in NHL indications (US$ millions)
  - Competitor ratio analysis
- Bexxar
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast Bexxar sales (US$ millions):
  - Competitor ratio analysis
- Zevalin
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast Zevalin sales (US$ millions)
  - Competitor ratio analysis
Marketed Agents for Cutatenous T-Cell Lymphoma
- Zolinza
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast Zolinza sales in CTCL (US$ millions)
  - Competitor ratio analysis
- Agents in Development
  - Drugs in development for the treatment of NHL:
  - Agents in late stage development for NHL:
- Treanda
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Treanda US sales forecasts in NHL indication (US$ millions)
  - Competitor ratio analysis
- ofatumumab
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Phase I/II trial results summary:
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast sales of ofatumumab in NHL by region (US$ millions):
  - Forecast sales of ofatumumab in NHL by use (US$ millions):
  - Competitor ratio analysis
- galiximab
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast galiximab sales in NHL (US$ millions)
  - Competitor ratio analysis
- pixantrone
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast pixantrone NHL sales by region (US$ millions):
  - Forecast pixantrone sales in NHL by use (US$ millions)
  - Competitor ratio analysis
- Revlimid
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Revlimid sales forecasts in NHL (US$ millions)
  - Competitor ratio analysis
- Torisel
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast Torisel sales in MCL (US$ millions)
  - Competitor ratio analysis
- Velcade
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast Velcade sales in MCL (US$ millions)
  - Forecast Velcade sales in follicular NHL (excludes MCL) by region (US$ millions)
  - Forecast Velcade sales in follicular NHL (excludes MCL) by use (US$ millions)
  - Competitor ratio analysis
- Inotuzumab Ozogamicin
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Competitor ratio analysis
Agents in Late Stage Development for Cutaneous T-Cell Lymphoma
- Zanliumumab
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast sales of zanolimumab in CTCL (US$ millions)
  - Competitor ratio analysis
- belinostat
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast sales of belinostat in CTCL (US$ millions)
  - Competitor ratio analysis
- Fodosine
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Forecast sales of Fodosine in CTCL (US$ millions)
  - Competitor ratio analysis
- Epratuzumab
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Competitor ratio analysis
- enzastaurin
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace/gaining share of voice
  - Risks associated with developing a drug within a therapeutic class
  - Filings and approval
  - Sales forecasts and assumptions
  - Competitor ratio analysis
CRA Analysis: AML
- CRA summary
CRA Analysis: CML
- CRA summary
CRA Analysis: CLL
CRA Analysis: Multiple Myeloma
- CRA Summary
CRA Analysis: NHL
- CRA analysis - NHL
- CRA analysis - NHL (continued)…includes CTCL
Acronyms

Blood Cancer Drug Discoveries: what the future holds

Table of Contents